Shaun Foy, CFA
Mr. Shaun Foy has almost 20 years of experience in emerging healthcare companies as an entrepreneur, investor and advisor. He co-founded CRISPR Therapeutics together with Dr. Emmanuelle Charpentier and Dr. Rodger Novak and served as Chief Business Officer and Chief Financial Officer until June 2015. He also co-founded and served as Chief Executive Officer of ERS Genomics, a company formed to provide broad access to the foundational CRISPR/Cas9 intellectual property in areas outside of human therapeutics. Shaun currently serves as a Venture Partner at SR One, and previously served as a Partner and one of the founding team members of Nomura Phase4 Ventures, a London-based venture capital group investing in emerging healthcare companies. He holds an M.Sc. in Cell Biology & Immunology and a B.Sc. in Cell & Developmental Biology, both from the University of British Columbia. He is also a Chartered Financial Analyst, or CFA.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.